AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9547130
Drug: Antidepressants (general)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (general)
Trial: 8396749
Drug: Simvastatin 5
RxNorm normalized name: simvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 5 mg evening dose for 8 weeks
Trial: 3453200
Drug: Quit Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quit Kit (self-administered smoking cessation program)
Trial: 27447719
Drug: MF102 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF102 4 g/day
Trial: 15564386
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy with an audiotape of classical music and ocean sounds during CNB
Trial: 15564386
Drug: 0.5-mg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg of alprazolam administered orally 15 minutes before CNB
Trial: 15564386
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (usual care, relaxation, medication)
Trial: 28341877
Drug: Daily prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisolone at 0.5 mg/kg for 5 days during URTI
Trial: 25605425
Drug: Mechanical debridement
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement (MDA) using carbon curettes and antiseptic therapy with chlorhexidine digluconate
Trial: 23312291
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment according to Federal and local medical recommendations
Trial: 8100428
Drug: Midazolam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.15 mg/kg and saline
Trial: 3209717
Drug: DA agonist
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA agonist (bromocriptine 5 mg orally)
Trial: 3209717
Drug: DA antagonist
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA antagonist (haloperidol 5 mg intravenously)
Trial: 3209717
Drug: Cholinergic agonist
RxNorm normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agonist (physostigmine 2 mg intravenously)
Trial: 3209717
Drug: Cholinergic antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cholinergic antagonist (benztropine 4 mg intravenously)
Trial: 31302525
Drug: Daily emotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily emotion reporting
Trial: 21295835
Drug: FSH (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH (25 mg im, twice daily for 4 days)
Trial: 21295835
Drug: eCG (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eCG (1000 IU as a single i.m. dose)
Trial: 11471907
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of melatonin 5 mg and zolpidem 10 mg
Trial: 9555553
Drug: Epirubicin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (40 mg/ml in normal saline) administered six times within 4 weeks after transurethral resection, followed by 11 additional monthly instillations of epirubicin
Trial: 9555553
Drug: Epirubicin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (40 mg/ml in normal saline) administered six times within 4 weeks after transurethral resection
Trial: 8177458
Drug: Estro-progestin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estro-progestin therapy
Trial: 3308192
Drug: Orbital cobalt
RxNorm normalized name: Cobalt
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital cobalt irradiation combined with retrobulbar methylprednisolone acetate (14 bilateral injections at 20-30 d intervals)
Trial: 3308192
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with systemic corticosteroids and orbital radiotherapy
Trial: 31774544
Drug: Micronized-isotretinoin 32
RxNorm normalized name: isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized-isotretinoin 32 mg (fed state)
Trial: 31774544
Drug: Lidose-isotretinoin 40
RxNorm normalized name: isotretinoin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidose-isotretinoin 40 mg (fed state)
Trial: 31774544
Drug: Micronized-isotretinoin 32
RxNorm normalized name: isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized-isotretinoin 32 mg (fasted state)
Trial: 31774544
Drug: Lidose-isotretinoin 40
RxNorm normalized name: isotretinoin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidose-isotretinoin 40 mg (fasted state)
Trial: 29506967
Drug: Self-administered Web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered Web-based questionnaires (SAQ-Web)
Trial: 29506967
Drug: Self-administered paper-based
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered paper-based questionnaires (SAQ-paper)
Trial: 14671175
Drug: 1000 mg/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/6 wk TU plus 20 mg/d CPA
Trial: 14671175
Drug: 1000 mg/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/8 wk TU plus 2 mg/d CPA
Trial: 14671175
Drug: 1000 mg/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/8 wk TU plus placebo
Trial: 10882331
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg granisetron + DEX
Trial: 10882331
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg granisetron + DEX
Trial: 8993943
Drug: Simvastatin and
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin and Ciprofibrate combination
Trial: 1730327
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) + ethinyl estradiol (E2)
Trial: 3881968
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (0.75 mg, 1.5 mg, or 2.25 mg)
Trial: 30316547
Drug: Individualised manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised manual therapy plus guideline-based advice (10 sessions)
Trial: 16236320
Drug: Lithium (300-1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (300-1800 mg/d)
Trial: 11822473
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (0.9 g x kg lean tissue mass(-1) x day(-1); n = 17)
Trial: 11822473
Drug: Placebo (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9 g maltodextrin x kg lean tissue mass(-1) x day(-1); n = 14)
Trial: 7746123
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment (1 g of ciprofloxacin in a single daily dose for 2 days)
Trial: 7746123
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (1 g of ciprofloxacin in two daily doses for 5 days)
Trial: 2643037
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once daily (with NSAIDs)
Trial: 2643037
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (with NSAIDs)
Trial: 2643037
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily (with NSAIDs)
Trial: 1172813
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of allopurinol (300 mg)
Trial: 1172813
Drug: Divided doses
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided doses of allopurinol (100 mg three times a day)
Trial: 31307833
Drug: CND 32
RxNorm normalized name: CNDO-109
DrugBank: CNDO-109 (DB17290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CND 32 mg/RSV 20 mg
Trial: 31307833
Drug: RSV 20
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV 20 mg
Trial: 31307833
Drug: CND 32
RxNorm normalized name: CNDO-109
DrugBank: CNDO-109 (DB17290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CND 32 mg
Trial: 28578844
Drug: Dual-Mobility (DM)
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-Mobility (DM) implant
Trial: 28578844
Drug: Single-Bearing (SB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Bearing (SB) implant
Trial: 24085378
Drug: Group exercise
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group exercise therapy (90 min under physiotherapist guidance)
Trial: 24085378
Drug: Group exercise
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group exercise therapy
Trial: 19114852
Drug: Etravirine 400
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine 400 mg twice daily
Trial: 19114852
Drug: Etravirine 800
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine 800 mg twice daily
Trial: 15575933
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg once daily for 8 days)
Trial: 15575933
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (250 microg twice daily for 8 days)
Trial: 10460064
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg bolus, 9 mg/kg/h infusion for 1 hour)
Trial: 2135834
Drug: Prednisone therapy
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone therapy (10 week course)
Trial: 498955
Drug: Exploratory laparotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploratory laparotomy with splenectomy after multiple chemotherapy
Trial: 498955
Drug: Chemotherapy producing
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy producing complete clinical remission
Trial: 31868879
Drug: Multimodality strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality strategy consisting of radical hysterectomy/perioperative chemotherapy
Trial: 31095683
Drug: Self-administered individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered individual treatment (SIT)
Trial: 31095683
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment (GT)
Trial: 26470422
Drug: Longidaze in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longidaze in addition to standard etiotropic antibacterial therapy
Trial: 26470422
Drug: Standard etiotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard etiotropic antibacterial therapy
Trial: 23357198
Drug: 1×10(10) IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1×10(10) IU of the vaccine
Trial: 23357198
Drug: 1×10(9) IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1×10(9) IU of the vaccine
Trial: 23357198
Drug: 1×10(8) IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1×10(8) IU of the vaccine
Trial: 20689977
Drug: Client-centered, supportive-experiential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centered, supportive-experiential group therapy (SET)
Trial: 15466071
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (0.025-0.04 mg/kg per day) plus conventional therapy
Trial: 11495269
Drug: Aerosol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol therapy (streptomycin and steroids)
Trial: 9692657
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg every other day
Trial: 7873824
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole 200 mg daily for 7 days
Trial: 7873824
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole 100 mg for 15 days
Trial: 3145677
Drug: Carboprost (15‐methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboprost (15‐methyl PGF2 alpha) administered 8 hours after ethacridine lactate instillation
Trial: 3145677
Drug: Carboprost (15‐methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboprost (15‐methyl PGF2 alpha) administered 4 hours after ethacridine lactate instillation
Trial: 3145677
Drug: Carboprost (15‐methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboprost (15‐methyl PGF2 alpha) administered 2 hours after ethacridine lactate instillation
Trial: 31845611
Drug: EEGer neurofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEGer neurofeedback software used for treatment
Trial: 26160879
Drug: pomalidomide +
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pomalidomide + low-dose dexamethasone
Trial: 26160879
Drug: high-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose dexamethasone
Trial: 23747759
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg in very elderly patients
Trial: 23747759
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg in nonelderly patients
Trial: 23747759
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg in very elderly patients
Trial: 18510659
Drug: tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine ER (4 mg) + tamsulosin (0.4 mg)
Trial: 18510659
Drug: tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin (0.4 mg)
Trial: 2143596
Drug: Triatec 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triatec 2.5 mg
Trial: 2143596
Drug: Triatec 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triatec 5 mg
Trial: 2143596
Drug: Triatec 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triatec 10 mg
Trial: 2143596
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20 mg Lasilix and Triatec 5 mg
Trial: 2143596
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment plan
Trial: 25596468
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive strategy (tirofiban infusion and coronary angiography within 6h)
Trial: 9192504
Drug: Subcutaneous salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous salmon calcitonin (SCSCT) 50 IU/day for 30 days
Trial: 9192504
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin (INSCT) 200 IU/day for 30 days
Trial: 3905052
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment in low-risk tercile (VA population)
Trial: 3905052
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment in high-risk tercile (VA population)
Trial: 3905052
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment in CASS
Trial: 3905052
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment in CASS
Trial: 26896456
Drug: sarolaner (Simparica™)
RxNorm normalized name: sarolaner Chewable Tablet [Simparica]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarolaner (Simparica™) 2-4 mg/kg
Trial: 26896456
Drug: afoxolaner (NexGard®)
RxNorm normalized name: afoxolaner Chewable Tablet [NexGard]
DrugBank: Afoxolaner (DB11369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: afoxolaner (NexGard®) 2.5-6.8 mg/kg
Trial: 24497345
Drug: CD133(+) BMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD133(+) BMC injection
Trial: 20215545
Drug: Lapatinib (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,500 mg once daily or 500 mg twice daily)
Trial: 11906798
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day buprenorphine
Trial: 2103759
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg t.d.s.)
Trial: 30897567
Drug: Power Point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Power Point Therapy (PPT) - 10 units of 10 min each
Trial: 30897567
Drug: Power Point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Power Point Therapy (PPT)
Trial: 28940353
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 6000 mg/day for 28 days
Trial: 27423164
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment following nonresponse to risperidone or placebo
Trial: 25273659
Drug: No nasogastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nasogastric intubation and early oral feeding (trial group)
Trial: 22886837
Drug: HPβCD diclofenac
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPβCD diclofenac 18.75 mg
Trial: 22886837
Drug: HPβCD diclofenac
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPβCD diclofenac 37.5 mg
Trial: 18511049
Drug: Tegaserod with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod with whole-dose PEG-E
Trial: 18511049
Drug: Tegaserod with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod with split-dose PEG-E
Trial: 18511049
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with whole-dose PEG-E
Trial: 18511049
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with split-dose PEG-E
Trial: 18511049
Drug: Whole-dose PEG-E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-dose PEG-E
Trial: 18511049
Drug: Split-dose PEG-E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose PEG-E
Trial: 8872728
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nitrendipine (Bypress; Bayer) 2 hours before SWL
Trial: 6385259
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 every 3 weeks)
Trial: 6385259
Drug: Mitoxantrone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (12 mg/m2 every 3 weeks)
Trial: 6385259
Drug: Doxorubicin or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin or Mitoxantrone (as secondary therapy)
Trial: 22709418
Drug: Balanced saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced saline solution (group 2)
Trial: 17686111
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray 110 microg
Trial: 2642329
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg) daily, taken twice daily
Trial: 135666
Drug: Adriamycin alone
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin alone (60 mg/m2 intravenously every 3 weeks)
Trial: 135666
Drug: Adriamycin plus
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin plus streptozotocin (adriamycin 60 mg/m2 every 3 weeks + streptozotocin 500 mg/m2/day intravenously for 5 days every 3 weeks)
Trial: 31586368
Drug: Internet-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based self-help program SaveMySkin (12-week program based on cognitive-behavioral therapy)
Trial: 22568471
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of DHA supplementation